Ambra Schianca-Carnevale

Milan, 20122, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Real-world patterns of post-progression treatment and outcomes in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors.

Real-world patterns of post-progression treatment and outcomes in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors.

Journal: The oncologist

Published: June 16, 2025

Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer.

Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer.

Journal: JAMA network open

Published: February 21, 2025

Current controversies in the use of Oncotype DX in early breast cancer.

Current controversies in the use of Oncotype DX in early breast cancer.

Journal: Cancer treatment reviews

Published: December 02, 2024

Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer.

Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 11, 2024

An international survey on the knowledge, attitudes and clinical patterns of use of medical cannabis for cancer care: The TASMAN study.

An international survey on the knowledge, attitudes and clinical patterns of use of medical cannabis for cancer care: The TASMAN study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 25, 2024

Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario.

Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario.

Journal: Current oncology (Toronto, Ont.)

Published: July 23, 2024

Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials.

Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials.

Journal: Cancers

Published: June 14, 2024

Co-Occurring Driver Genomic Alterations in Advanced Non-Small-Cell Lung Cancer (NSCLC): A Retrospective Analysis.

Co-Occurring Driver Genomic Alterations in Advanced Non-Small-Cell Lung Cancer (NSCLC): A Retrospective Analysis.

Journal: Journal of clinical medicine

Published: May 28, 2024

Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials.

Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 03, 2024

The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics.

The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics.

Journal: Genes

Published: April 17, 2024

Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study.

Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study.

Journal: ESMO open

Published: April 09, 2024

Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution.

Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution.

Journal: Cancers

Published: January 13, 2023

Showing 1-12 of 12

Last Updated: 09/26/2026